Ankylosing spondylitis and the gut microbiome: future research hotspots and trends.

TL;DR

A systematic review of 280 published studies identifies inflammation, HLA-B27, probiotics, and short-chain fatty acids as current research hotspots in the relationship between gut bacteria and ankylosing spondylitis. The field is expanding rapidly but needs prospective studies to establish causality .

What the Study Found

Researchers at multiple institutions conducted a bibliometric analysis of published literature on ankylosing spondylitis (AS) and the gut microbiome. They searched two major databases (Web of Science and PubMed) through early 2026 and identified 280 total articles meeting their criteria. This type of analysis doesn't test new interventions but rather maps the landscape of existing research to identify patterns, trends, and areas of focus.

The data shows this is an increasingly active area of investigation. Annual publication volume and citation counts both increased over time, suggesting growing scientific interest and influence. China led in publication output with 60 articles, followed by the USA with 36. The most prolific authors were Brown, Ma, and Liu B. Major contributing research institutions clustered primarily in China and the USA, indicating concentration of effort in these regions.

The researchers identified five major research hotspots currently dominating the field. Inflammation emerged as a central theme, reflecting the autoimmune nature of AS. The genetic marker HLA-B27 represents another focus area, as it's strongly associated with AS susceptibility. Probiotics (live microorganisms intended to benefit health) and short-chain fatty acids (metabolites produced when gut bacteria ferment dietary fiber) rounded out the top research priorities. Mendelian randomization, a statistical method for inferring causality from genetic data, also featured prominently. This suggests researchers are trying to move beyond association studies toward establishing whether microbiome changes actually cause AS or simply occur alongside it.

A validation check using the PubMed database alone (115 articles) confirmed these same hotspots and trends, increasing confidence in the overall findings. The concordance between databases suggests the identified patterns reflect genuine research priorities rather than database-specific artifacts.

What This Means for You

This review is a research landscape analysis, not a clinical trial, so it doesn't establish whether any specific intervention works for AS. However, it clarifies what the scientific community is investigating. If you have ankylosing spondylitis, several implications merit attention.

First, the prominence of probiotics and short-chain fatty acids in current research reflects genuine scientific interest in whether microbiome modulation could play a role in AS management. However, "interest" does not equal "proven effective." The authors explicitly note that future researchers must conduct prospective studies to confirm causality. This means most current evidence remains observational and suggestive rather than definitive.

Second, the focus on HLA-B27 reminds us that AS involves both genetic and environmental factors. Your microbiome may influence disease expression, but genetics clearly matter too. This aligns with the current understanding that AS results from a combination of genetic predisposition and environmental triggers.

Third, if you're considering microbiome-targeted approaches (dietary changes, fermented foods, or supplements targeting gut health), recognize that this remains an active research frontier. The evidence supporting specific interventions is still developing. Prospective clinical trials with appropriate control groups remain needed.

The authors highlight an important gap: most current research is correlational. We know the microbiota differs in people with AS compared to healthy controls, but causality remains unclear. Does dysbiosis drive disease? Does disease cause dysbiosis? Or do they share a common cause? The field is working toward answers, but they're not yet definitive.

Practically, this suggests patience and skepticism toward premature claims about microbiome-based AS treatments. Work with your healthcare provider on evidence-based management approaches while staying informed about emerging research.

Study Details

Sources

Brown, Ma, Liu B et al. Ankylosing spondylitis and the gut microbiome: future research hotspots and trends. *Frontiers in Immunology*. 2026. PubMed: 42164510